MedTrace Logo

Observational Study to Evaluate the Actual Use of Elidel® in Chinese Patients With Mild to Moderate Atopic Dermatitis

NCT04976868 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2023-05-24

No results posted yet for this study

Summary

The primary objective of the present multicentre, prospective, non-interventional study (NIS) is gathering knowledge on the actual use and effectiveness of Elidel® in Chinese patients with mild to moderate AD affecting sensitive skin areas in routine clinical practice.

Conditions

Interventions

DRUG

Pimecrolimus 1% Top Cream

Elidel® as prescribed within routine clinical practice

Sponsors & Collaborators

  • Medicine Meda Pharmaceutical Information Consultancy (Beijing) Co., Ltd.

    collaborator INDUSTRY

  • Mylan Inc.

    lead INDUSTRY

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-18
Primary Completion
2022-10-31
Completion
2022-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04976868 on ClinicalTrials.gov